1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. Вестн. Рос. онкол. центра им. Н.Н.Блохина РАМН. 2009; 20, 3 (прил. 1).
2. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Brit J Cancer 2009; 100: 1704–19.
3. Nordlinger B, Van Cutsem E, Rougier P et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. EJC 2007; 43: 2037–45.
4. Jan HM. Schellens. Cancer clinical pharmacology. Oxford Univercity Press. 2006; p. 52.
5. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–8.
6. Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rates. J Clin Oncol 1992; 10: 904–11.
7. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766–75.
8. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly lowdose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808–15.
9. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–8.
10. Maughan TS, James RD, Kerr DJ et al. Preliminary results of multicenter randomized trail comparing 3 chemotherapy regimens (de Gramont, Lokich, and Raltitrexed) in metastatic colorectal cancer. Proceedings of American Society of clinical Oncology 1999; 18: 262a.
11. Pentheroudakis G, Twelves C. The rational development of capecitabine from the laboratory to the clinic. Anticancer Res 2002; 22: 3589–96.
12. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097–106.
13. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282–92.
14. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007; 30: 4779–86.
15. Porschen R, Arkenau HT, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217–23.
16. Diaz-Rubio E, Tabernero J, Gomez-Espan A et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-Line therapy in metastatic colorectal cancer: final report of the spanish cooperative group for the treatment of digestive tumors trial. J Clin Oncol 2007; 25 (27).
17. Ducreux M, Bennouna J, Hebbar M et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol (Meeting Abstracts) 2007; 25: 4029.
18. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008; 26 (21): 3523–9.
19. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–8.
20. Saltz LB, Douillard J, Pirrotta N et al. Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs. F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC). Proc ASCO 2000; 19: 242a.
21. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–7. [Erratum, Lancet 2000; 355: 1372.]
22. Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trails in advanced colorectal cancer. Semin Oncol 1998; 25 (Suppl. 5): 23–31.
23. Raymond E, Buquet-Fagot C, Djelloul S et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8: 876–85.
24. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47.
25. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil–leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil–leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21 (11): 2059–69.
26. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229–37.
27. Goldberg RM, Sargent DJ, Morton RF et al. N9741: FOLFOX (oxaliplatin (Oxal)/5-fluorouracil (5-FU)/leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): final efficacy data from an intergroup study. J Clin Oncol 2004; 22 (Suppl.): 3621. abstract.
28. Colucci G, Gebbia V, Paolett G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005; 23 (22): 4866–75.
29. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209–14.
30. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670–6.
31. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011–27.
32. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15: 102–11.
33. Lu J, Gaudreault J, Novotny W et al. A population pharmacokinetic model for bevacizumab. Clin Pharmacol Ther 2004; 75: 91 (abstr PII-149).
34. Prewett M, Huber J, Li Y et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209–18.
35. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60–5.
36. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
37. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
38. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013–9.
39. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). ASCO 2007 Gastrointestinal Cancers Symposium abst. 238.
40. Tebbutt N, Gebski V, Wilson K et al. International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial. Eur J Cancer Suppl. 2009; 7 (2): 321.
41. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21 (14): 2787–99.
42. Mayer A, Takimoto M, Fritz E et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71 (8): 2454–60.
43. Tabernero J, Ciardiello F, Rivera F et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol 2009; doi:10.1093/annonc/mdp549.
44. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508–15.
45. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166–9.
46. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374–9.
47. Van Cutsem E, Lang I, Folprecht G et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. J Clin Oncol 2010 (Gastrointestinal Cancers Symposium); 281 (abstr.): 4000.
48. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663–71.
49. Van Cutsem E et al. ECCO/ESMO Congress 2009; Abstract No: 6077.
50. T. Maughan RA, Adams CG, Smith et al. Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). Eur J Cancer 2009; 7 (3): 4 (abstr 6LBA).
51. Douillard JY, Siena S, Cassidy J. et al. Randomized Phase 3 Study of Panitumumab with FOLFOX4 vs FOLFOX4 Alone as First-line Treatment in Patients with Metastatic Colorectal Cancer: the PRIME Trial. Eur J Cancer 2009; 7 (3 suppl.): 10LBA.
52. Saltz LB, Lenz HJ, Kindler HL et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25: 4557–61.
53. Hecht JR, Mitchell E, Chidiac T et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. JCO 2009; 672–80.
54. Aschele C, Bergamo F, Lonardi S. Chemotherapy for operable and advanced colorectal cancer. Cancer Treatment Rev 2009; 35: 509–16.
55. Weber SM et al. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000; 7: 643–50.
56. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309–18.
57. Tabernero J, Van Cutsem E, D?az-Rubio E et al. Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer. JCO 2007; 5225–32.
58. Garufi C, Torsello A, Tumolo S et al. POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). J Clin Oncol 2009; 27: suppl. abstr e15020. 2009 ASCO Annual Meeting.

М.Ю.Федянин, А.А.Трякин, С.А.Тюляндин

ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва